The tweet was deleted by the author.
But we saved everything 🙂.
Arcus Biosciences announced a clinical supply agreement with AVEO Oncology to evaluate casdatifan in combination with a VEGFR tyrosine kinase inhibitor.
The companies will conduct the evaluation in a new cohort of the ARC-20 platform study for patients with advanced disease. Arcus Biosciences described casdatifan as an investigational HIF-2α inhibitor.
View post on X Loading...
RCUS is trading at $29.97, above the MA-20 ($29.24), MA-50 ($26.21), and MA-200 ($22.73), which signals ongoing bullish structure across short-, medium-, and long-term trends. The Ichimoku Kijun level on D1 sits at $27.52, marking immediate support near current levels; near-term support is at $29.24 (MA-20) and key support at $26.21 (MA-50), with near-term resistance at $31.74 (52-week high, just above) and key resistance at $29.97 (current top of weekly range).
Momentum signals remain positive. MACD on D1 gives a strong buy, but ADX on D1 is low at 14.91 and neutral, suggesting the trend may lack true conviction. RSI on D1 reads 58, a bullish but not overheated zone. However, Stoch RSI and CCI on D1 are both neutral, while BBP on D1 is overbought with a reading of 1.07, signaling strong buyer dominance. The Awesome Oscillator also confirms the bullish tone. In today's session, RCUS is up 1.66% and trading at the very top of its weekly range following a robust 9.5% rally from a prev_week_close of $27.37, with weekly volatility standing at 15.15%. The move reflects aggressive upside momentum with minor signs of possible exhaustion at these highs.
Looking ahead, the expected trading range for the next week is estimated at $28.00 to $32.75, adjusted to fit within a realistic band around the current price and based on typical volatility. This range places RCUS closer to its 52-week high ($31.74) and well above the annual low of $8.84. With all W1 indicators—MA-50, RSI, ADX, and MACD—generating buy signals, the probability of further price appreciation is very high (more than 80%), while a pullback is less likely. Baseline scenario sees price holding between $28.00 and $32.75 as momentum cools near resistance. A bullish scenario could see RCUS breaking above $32.75 towards its yearly high if buyer pressure persists. On the downside, a break below $28.00 may trigger profit-taking and a pullback toward stronger supports at $26.21 and $24.66.
Previously it was reported that Arcus Biosciences maintained a strong bullish trend despite encountering short-term volatility and a technical pullback. As new developments unfold, traders should monitor for shifts in trend strength that could present actionable opportunities in the sessions ahead.